Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma

Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor receptor variant III (CAR T-EGFRvIII) have been developed and administered experimentally to treat patients with IDH1 wildtype recurrent glioblastoma (rGBM) (NCT02209376). We report the case of a 59-year-old patie...

Full description

Bibliographic Details
Main Authors: Joseph S. Durgin, Fraser Henderson, MacLean P. Nasrallah, Suyash Mohan, Sumei Wang, Simon F. Lacey, Jan Joseph Melenhorst, Arati S. Desai, John Y. K. Lee, Marcela V. Maus, Carl H. June, Steven Brem, Roddy S. O’Connor, Zev Binder, Donald M. O’Rourke
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
CAR T cell therapy
glioblastoma
EGFRvIII
recurrent glioblastoma (rGBM)
CAR (chimeric antigen receptor)
perfusion imaging
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.669071/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.669071/full

Similar Items